<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">A panel of pediatric infectious disease physicians and pharmacists from North America has recommended Remdesivir as a preferred antiviral agent followed by Hydroxychloroquine for children with positive virologic COVID-19 testing [
 <xref rid="bib34" ref-type="bibr">34</xref>]. This recommendation was subsequently endorsed by The Pediatric Infectious Diseases Society. Hydroxychloroquine may be considered (with careful consideration of its potential toxicities, particularly those related to QTc prolongation) as an alternative to Remdesivir in countries where the latter drug is not available or the patient is not a candidate for Remdesivir.
</p>
